CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA

CytoDyn Inc. , a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, ... (more)

http://www.freshnews.com/news/864215/cytodyn-submits-phase-iib-protocol-pro-140-clinical-trial-fda